Industry weighs the pros and cons of an Obama-appointed Federal Insurance Czar.
The Obama administration is said to be facing different perspectives regarding the establishment of a Federal Insurance Czar or the Health Choices Commissioner. On one hand, state regulators believe a federal czar is not needed. Meanwhile, some consumer groups believe that a federal insurance commissioner can help keep insurers honest.
Joseph Mack, president, Joseph Mack & Associates, healthcare business advisors in Dana Point, Calif., believes that managed care executives should not spend resources analyzing the potential effects of a Federal Czar.
“Executives should be focusing their resources on defining, quantifying and implementing clinical best practice standards,” Mack says. “Evidence shows and public opinion overwhelmingly believes that healthcare costs continue to rise while the definition of quality is ill-defined at best.
“Short of a complete government takeover of healthcare, competition will be won based on quality and cost. The best quality care is the most cost-effective. The ability for MCOs to quantifiably demonstrate they are market leaders in quality and cost will enable them to succeed.”
How an MCO positions itself to best prosper in any potential national healthcare program can be assessed and planned for once the details and structure of a potential national healthcare program materialize, according to Mack.
“Demonstrating that they are the highest, most cost-effective organizations will best serve MCOs regardless of whether healthcare reform passes in 2009 or the future,” he says.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More